Literature DB >> 24497185

Universal public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis.

Stéphane Verguet1, Ramanan Laxminarayan, Dean T Jamison.   

Abstract

Universal public finance (UPF)-government financing of an intervention irrespective of who is receiving it-for a health intervention entails consequences in multiple domains. First, UPF increases intervention uptake and hence the extent of consequent health gains. Second, UPF generates financial consequences including the crowding out of private expenditures. Finally, UPF provides insurance either by covering catastrophic expenditures, which would otherwise throw households into poverty or by preventing diseases that cause them. This paper develops a method-extended cost-effectiveness analysis (ECEA)-for evaluating the consequences of UPF in each of these domains. It then illustrates ECEA with an evaluation of UPF for tuberculosis treatment in India. Using plausible values for key parameters, our base case ECEA concludes that the health gains and insurance value of UPF would accrue primarily to the poor. Reductions in out-of-pocket expenditures are more uniformly distributed across income quintiles. A variant on our base case suggests that lowering costs of borrowing for the poor could potentially achieve some of the health gains of UPF, but at the cost of leaving the poor more deeply in debt.
© 2014 The Authors. Health Economics published by John Wiley Ltd.

Entities:  

Keywords:  India; extended cost-effectiveness analysis; financial protection; health policy instruments; insurance; public finance; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24497185     DOI: 10.1002/hec.3019

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  52 in total

1.  Defining Pathways and Trade-offs Toward Universal Health CoverageComment on "Ethical Perspective: Five Unacceptable Trade-offs on the Path to Universal Health Coverage".

Authors:  Stéphane Verguet
Journal:  Int J Health Policy Manag       Date:  2016-07-01

2.  HTA - Algorithm or Process? Comment on "Expanded HTA: Enhancing Fairness and Legitimacy".

Authors:  Anthony J Culyer
Journal:  Int J Health Policy Manag       Date:  2016-08-01

3.  How much do Indians pay for tuberculosis treatment? A cost analysis.

Authors:  P Sinha; M Carwile; A Bhargava; C Cintron; C Acuna-Villaorduna; S Lakshminarayan; A F Liu; N Kulatilaka; L Locks; N S Hochberg
Journal:  Public Health Action       Date:  2020-09-21

4.  Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.

Authors:  Thomas Ward; Ruben E Mujica-Mota; Anne E Spencer; Antonieta Medina-Lara
Journal:  Pharmacoeconomics       Date:  2021-10-29       Impact factor: 4.981

5.  Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

Authors:  Alyssa Bilinski; Evan MacKay; Joshua A Salomon; Ankur Pandya
Journal:  Value Health       Date:  2022-02-24       Impact factor: 5.101

6.  Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.

Authors:  Itamar Megiddo; Eili Klein; Ramanan Laxminarayan
Journal:  BMJ Glob Health       Date:  2018-05-09

Review 7.  Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition.

Authors:  Dean T Jamison; Ala Alwan; Charles N Mock; Rachel Nugent; David Watkins; Olusoji Adeyi; Shuchi Anand; Rifat Atun; Stefano Bertozzi; Zulfiqar Bhutta; Agnes Binagwaho; Robert Black; Mark Blecher; Barry R Bloom; Elizabeth Brouwer; Donald A P Bundy; Dan Chisholm; Alarcos Cieza; Mark Cullen; Kristen Danforth; Nilanthi de Silva; Haile T Debas; Peter Donkor; Tarun Dua; Kenneth A Fleming; Mark Gallivan; Patricia J Garcia; Atul Gawande; Thomas Gaziano; Hellen Gelband; Roger Glass; Amanda Glassman; Glenda Gray; Demissie Habte; King K Holmes; Susan Horton; Guy Hutton; Prabhat Jha; Felicia M Knaul; Olive Kobusingye; Eric L Krakauer; Margaret E Kruk; Peter Lachmann; Ramanan Laxminarayan; Carol Levin; Lai Meng Looi; Nita Madhav; Adel Mahmoud; Jean Claude Mbanya; Anthony Measham; María Elena Medina-Mora; Carol Medlin; Anne Mills; Jody-Anne Mills; Jaime Montoya; Ole Norheim; Zachary Olson; Folashade Omokhodion; Ben Oppenheim; Toby Ord; Vikram Patel; George C Patton; John Peabody; Dorairaj Prabhakaran; Jinyuan Qi; Teri Reynolds; Sevket Ruacan; Rengaswamy Sankaranarayanan; Jaime Sepúlveda; Richard Skolnik; Kirk R Smith; Marleen Temmerman; Stephen Tollman; Stéphane Verguet; Damian G Walker; Neff Walker; Yangfeng Wu; Kun Zhao
Journal:  Lancet       Date:  2017-11-25       Impact factor: 79.321

8.  Balancing health and financial protection in health benefit package design.

Authors:  Katherine T Lofgren; David A Watkins; Solomon T Memirie; Joshua A Salomon; Stéphane Verguet
Journal:  Health Econ       Date:  2021-10-08       Impact factor: 2.395

9.  Health gains and financial risk protection: an extended cost-effectiveness analysis of treatment and prevention of diarrhoea in Ethiopia.

Authors:  Clinton J Pecenka; Kjell Arne Johansson; Solomon Tessema Memirie; Dean T Jamison; Stéphane Verguet
Journal:  BMJ Open       Date:  2015-05-03       Impact factor: 2.692

10.  Valuing Protection against Health-Related Financial Risks.

Authors:  Jonathan Skinner; Kalipso Chalkidou; Dean T Jamison
Journal:  J Benefit Cost Anal       Date:  2019-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.